Literature DB >> 3977335

Fluorouracil paste treatment of thin basal cell carcinomas.

E Epstein.   

Abstract

Treatment of thin (superficial) basal cell carcinomas (BCCs) with topical fluorouracil is widely accepted despite the absence of published five-year cure rates. The published short-term data disclose treatment failure rates substantially higher than other modalities. In trials to improve and standardize topical fluorouracil therapy, thin BCCs were treated with 25% fluorouracil in petrolatum under occlusion for three weeks using weekly dressing changes. Of 44 thin BCCs treated only with 25% fluorouracil under occlusion for three weeks, the five-year cumulative recurrence rate was 21%. In a second series of 244 BCCs, light curettage preceded the 25% fluorouracil treatment to yield a five-year cumulative recurrence rate of 6%. Cosmetic results were good to excellent in more than 80% of both series. While fluorouracil by itself is not a satisfactory treatment for thin BCC, when combined with light curettage, topical fluorouracil therapy is capable of cure rates competitive with other modalities.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3977335

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  5 in total

1.  Nonsurgical innovations in the treatment of nonmelanoma skin cancer.

Authors:  Sadegh Amini; Martha H Viera; Whitney Valins; Brian Berman
Journal:  J Clin Aesthet Dermatol       Date:  2010-06

Review 2.  Diagnosis and Management of Basal Cell Carcinoma.

Authors:  Keiji Tanese
Journal:  Curr Treat Options Oncol       Date:  2019-02-11

Review 3.  Basal Cell Carcinoma: A Comprehensive Review of Existing and Emerging Nonsurgical Therapies.

Authors:  Julien Lanoue; Gary Goldenberg
Journal:  J Clin Aesthet Dermatol       Date:  2016-05-01

4.  Skin cancer and the solid organ transplant recipient.

Authors:  M J Patel; N J Liégeois
Journal:  Curr Treat Options Oncol       Date:  2009-02-19

Review 5.  Pharmacological treatments for basal cell carcinoma.

Authors:  Seongmu Lee; Dinesh Selva; Shyamala C Huilgol; Robert A Goldberg; Igal Leibovitch
Journal:  Drugs       Date:  2007       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.